QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
69.61
-0.04 (-0.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close69.65
Open69.68
Bid0.00 x 900
Ask0.00 x 1300
Day's Range68.74 - 71.00
52 Week Range21.98 - 82.49
Volume343,690
Avg. Volume706,864
Market Cap2.629B
Beta (3Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-2.48
Earnings DateMay 30, 2017 - Jun 2, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est86.15
Trade prices are not sourced from all markets
  • Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
    Zacks6 days ago

    Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)

    Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.

  • What Drove uniQure 171% Higher in the First Half of 2019
    Motley Fool9 days ago

    What Drove uniQure 171% Higher in the First Half of 2019

    Steady progress with experimental gene therapies gave investors reasons to cheer.

  • GlobeNewswire11 days ago

    uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

    ~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of.

  • How Much Of uniQure N.V. (NASDAQ:QURE) Do Institutions Own?
    Simply Wall St.15 days ago

    How Much Of uniQure N.V. (NASDAQ:QURE) Do Institutions Own?

    The big shareholder groups in uniQure N.V. (NASDAQ:QURE) have power over the company. Institutions often own shares in...

  • Benzinga18 days ago

    The Week Ahead In Biotech: Pending Clinical Readouts In Focus

    Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...

  • Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)
    Insider Monkey24 days ago

    Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE)

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • GlobeNewswire26 days ago

    uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.

  • The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
    Zacks27 days ago

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

  • Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
    Zacks28 days ago

    Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

    A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

  • Zacks29 days ago

    Fed Week Begins in the Green

    Fed Week Begins in the Green

  • Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst
    Investor's Business Dailylast month

    Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst

    Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.

  • Gene-Therapy Firm UniQure Explores Options Including Sale
    Bloomberglast month

    Gene-Therapy Firm UniQure Explores Options Including Sale

    (Bloomberg) -- UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said. The shares jumped.The biotechnology company is working with advisers as it weighs options including a sale or partnerships, according to the people, who asked not to be identified because the information is private. UniQure’s shares have risen more than 151% in New York this year, giving it a market value of about $2.7 billion.UniQure shares rose as much as 9.2% to $79.20 in New York, the stock’s highest-ever intraday price.Major pharmaceutical firms have been pursuing gene-therapy companies that promise to treat rare, debilitating diseases by correcting DNA flaws. While the field has yet to deliver a blockbuster, the promise of dramatic cures carrying multimillion-dollar price tags has triggered a flurry of deal activity. Cantor Fitzgerald LP said in February that UniQure “could be next” and may attract interest from large-cap companies such as Novo Nordisk A/S, Pfizer Inc. and Sanofi.A deal with UniQure would bring access to a pipeline of experimental treatments for hemophilia, Huntington’s disease and other disorders. The company is incorporated in the Netherlands, with about 200 employees spread between Amsterdam and Lexington, Massachusetts, according to its website.Read more: After $1 Million Drug Flop, UniQure Revives in Gene TherapyUniQure shares surged earlier this month after it canceled plans to attend Goldman Sachs Group Inc.’s annual health-care conference. The company said it pulled out due to a conflict with Chief Executive Officer Matt Kapusta’s schedule.No final decisions have been made, and there’s no certainty the deliberations will lead to a transaction, the people said. A representative for UniQure declined to comment.Biogen Inc. agreed earlier this year to buy Nightstar Therapeutics Plc, and Pfizer bought a stake in Vivet Therapeutics. Roche Holding AG agreed in February to acquire Spark Therapeutics Inc. for $4.8 billion, following Novartis AG’s $8.7 billion purchase of AveXis Inc. last year.UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn’t renew its marketing authorization in 2017. Since then, the company has focused on hemophilia treatments.Gene therapy deals are starting to face some scrutiny from regulators. Earlier this month, the U.S. Federal Trade Commission asked Roche and Spark for more information as part of its review of their pending deal. The latest FTC request came after the agency said in April it would need more time to examine the transaction.(Updates with opening shares in the third paragraph.)\--With assistance from James Paton and Ruth David.To contact the reporters on this story: Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Ed Hammond in New York at ehammond12@bloomberg.netTo contact the editors responsible for this story: Dinesh Nair at dnair5@bloomberg.net, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • TheStreet.comlast month

    UniQure Jumps on Report It's Exploring a Possible Sale

    jumped Monday after a report said the biotechnology company was exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy. UniQure is working with advisers as it weighs options including a sale or partnerships, Bloomberg reported, citing people with knowledge of the matter. UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn't renew its marketing authorization in 2017.

  • Is the Options Market Predicting a Spike in uniQure (QURE) Stock?
    Zackslast month

    Is the Options Market Predicting a Spike in uniQure (QURE) Stock?

    Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.

  • AMD and 3 more momentum stocks to watch
    MarketWatchlast month

    AMD and 3 more momentum stocks to watch

    These four stocks in the high-momentum technology, biotech and mining areas are on the move. Advanced Micro Devices (AMD)  leapt $1.99 to $29.57 on 107 million shares Tuesday. On Monday the chip maker announced a deal to license its custom graphics intellectual property to Samsung for use in mobile devices.

  • An Intrinsic Calculation For uniQure N.V. (NASDAQ:QURE) Suggests It's 29% Undervalued
    Simply Wall St.last month

    An Intrinsic Calculation For uniQure N.V. (NASDAQ:QURE) Suggests It's 29% Undervalued

    In this article we are going to estimate the intrinsic value of uniQure N.V. (NASDAQ:QURE) by taking the expected...

  • uniQure (QURE) Jumps: Stock Rises 8.9%
    Zackslast month

    uniQure (QURE) Jumps: Stock Rises 8.9%

    uniQure (QURE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • GlobeNewswire2 months ago

    uniQure to Participate in Multiple Upcoming Industry Conferences

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 31, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.

  • 3 Top Gene Therapy Stocks That Could Soar
    InvestorPlace2 months ago

    3 Top Gene Therapy Stocks That Could Soar

    Thanks to advances in technology and gene sequencing, gene therapy has gone from science fiction to science fact. By either adding new genes to fight faulty ones, replacing/editing missing/broken prices or actually "turning off" the genes causing problems, gene therapy has the potential to change the game when it comes to biotech stocks and healthcare.That's great news, as there are more than 10,000 different disorders and diseases caused by faulty genes.With the FDA launching several fast-track programs for gene therapies last summer, the biotech stocks that specialize in these cutting-edge treatments could see their drugs hit the market that much faster. And yet, the recent market sell-off has caused many of the biotech stocks looking at gene therapy to crater. Given their game-changing potential, these days many stocks in the sector could be considered bargains.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSome more than others. * 7 Stocks to Sell Amid an Escalating Trade War Which gene-therapy biotech stocks have great potential to soar over the long haul? Here are three stocks to buy that could do just that. Gene Therapy Stocks to Buy: CRISPR Therapeutics (CRSP)Source: Shutterstock Clustered Regularly Interspaced Short Palindromic Repeats is a mouthful to say, which is why scientists have shortened it to just CRISPR. CRISPR is the latest method of gene editing and offers cheaper, simpler and faster slicing and dicing of genes. As its name implies, CRISPR Therapeutics (NASDAQ:CRSP) uses the technique.CRSP stock is targeting blood diseases such as beta-thalassemia and sickle cell disease- which are caused by the same mutation. The beauty of this is that the biotech has been able to move ahead at the same time for both indications. Partnering with biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX), CRSP's lead candidate -- CTX001 -- started phase 1 clinical trials this past February. This trial marks the first time in history that a human trial for a CRISPR-based product has been conducted.Naturally, a lot is riding on the trial- especially with the drug winning FDA fast track status. If results are even somewhat positive, CRSP stock could surge higher.But CTX001 isn't the only drug in CRSP's arsenal. The firm is working one several oncology products as well as new gene editing therapies for muscular dystrophy and cystic fibrosis. These drugs could provide plenty of upside as well down the road.In the end, if you're looking for biotech stocks to buy that are looking at gene therapy, CRISPR Therapeutics could be a major star. uniQure NV (QURE)Source: Shutterstock When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That's because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development.This includes the biotech stock's latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication -- AMT-061 -- into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand.Elsewhere, the firm has started trials for the first gene therapy targeting Huntington's disease and has gene therapies for congestive heart failure in pipelines. All of these are much more "popular" issues and should help QURE actually see prescription growth if successful. * 7 Stocks to Buy for June Like most clinical-stage biotech stocks, QURE is a gamble. But it's a more calculated risk than most given its history and how great its previous results were. Voyager Therapeutics (VYGR)Source: Shutterstock When it comes to clinical stage biotech stocks, it pays to look at partnerships. For gene therapy play Voyager Therapeutics (NASDAQ:VYGR), partnerships include biotech giant AbbVie (NYSE:ABBV), neurological specialist Neurocrine Biosciences (NASDAQ:NBIX) and major pharma stock Sanofi (NASDAQ:SNY). All three of those major players have provided VYGR with some major cash infusions to develop its technology and gene therapy applications. Most clinical biotech stocks would kill to have more than $360 million in cash on their balance sheets.That cash will provide it plenty of working capital to develop its lucrative gene therapy portfolio.And lucrative it will be. VYGR is targeting Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease and Alzheimer's disease. These are some of the hardest diseases to crack and winners here will be massive achievements. It seems that Voyager may just get there.So far, results for the firm's tech have been pretty positive, which could explain all the major partnerships. Back in March, Voyager announced that its initial trial for VY-AADC demonstrated improvement in clinical measures for Parkinson's Disease. This success prompted VYGR to start phase II trials -- with results coming in mid-2020. Meanwhile, the firm is moving forward with initial trials with its other partners and developing a robust pipeline. With ample cash, VYGR has plenty of time to get these therapies through testing. Fast track designation from the FDA doesn't hurt either.All in all, VYGR represents a great gene therapy play thanks to its leading partners. Clearly, they see the good in the biotech stocksAt the time of writing, Aaron Levitt was long CRSP and VYGR stock More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Amid an Escalating Trade War * 5 REITs to Buy While They're Dirt Cheap * The Only 3 Marijuana Stocks You Need to Own Compare Brokers The post 3 Top Gene Therapy Stocks That Could Soar appeared first on InvestorPlace.

  • GlobeNewswire2 months ago

    uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 22, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the issuance of two new patents covering AMT-130, the Company’s gene therapy candidate for the treatment of Huntington’s disease. AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette, encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients. The U.S. Patent and Trademark Office issued U.S. Patent 10,174,321 on January 8, 2019 and the European Patent Office issued EP 3237618 on May 22, 2019.

  • This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study
    Investor's Business Daily2 months ago

    This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study

    UniQure stock approached a breakout Friday after its experimental gene therapy showed improving promise in hemophilia B treatment. Shares are consolidating with a buy point at 69.70.

  • uniQure N.V. (NASDAQ:QURE) Insiders Have Been Selling
    Simply Wall St.2 months ago

    uniQure N.V. (NASDAQ:QURE) Insiders Have Been Selling

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • GlobeNewswire2 months ago

    uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B

    ~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor.

  • GlobeNewswire2 months ago

    uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting

    The abstract entitled, “Development of an AAV-based microRNA Gene Therapy for Treating Spinocerebellar Ataxia Type 3,” is being recognized by the American Academy of Neurology for dual oral and poster presentations during its annual meeting taking place this week in Philadelphia, PA. Spinocerebellar Ataxia Type 3, also known as Machado-Joseph disease, is caused by a CAG-repeat expansion in the ATXN3 gene that results in an abnormal form of the toxic protein ataxin-3, leading to brain degeneration that results in movement disorders, rigidity, muscular atrophy and paralysis.

  • Did Hedge Funds Drop The Ball On Uniqure NV (QURE) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Uniqure NV (QURE) ?

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]